[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Lee DW, Kim YT, Kim JH, Kim S, Kim SW, Nam EJ, Kim JW: Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. J Gynecol Oncol; 2010 Mar;21(1):18-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy.
  • OBJECTIVE: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy.
  • METHODS: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated with concurrent weekly cisplatin (40 mg/m(2)) and radiotherapy between January 2000 and April 2007.
  • Potential prognostic factors were age, chemotherapy numbers, histology, tumor diameter and volume, lymph node (LN) involvement and pretreatment squamous cell carcinoma antigen (SCC-Ag) levels.
  • CONCLUSION: Tumor volume and pelvic LN involvement showed possibility to predict overall survival in patient with stage IIB cervical cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Q. 1994 Mar;10(1):22-42 [8161484.001]
  • [Cites] Cancer. 1990 May 1;65(9):1923-7 [2372764.001]
  • [Cites] AJR Am J Roentgenol. 1996 Nov;167(5):1101-8 [8911159.001]
  • [Cites] AJR Am J Roentgenol. 1998 Sep;171(3):707-11 [9725301.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1547-54 [10193945.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):639-44 [10524417.001]
  • [Cites] Zentralbl Gynakol. 2000;122(2):82-91 [10721187.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):263-71 [11520363.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):115-9 [11748986.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):14-22 [11777618.001]
  • [Cites] Radiol Clin North Am. 2002 May;40(3):577-90, vii [12117194.001]
  • [Cites] Acta Obstet Gynecol Scand. 2002 Dec;81(12):1144-51 [12519111.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):e163-8 [14528092.001]
  • [Cites] Tumour Biol. 2003 May-Jun;24(3):156-64 [14610320.001]
  • [Cites] J Comput Assist Tomogr. 2004 Sep-Oct;28(5):620-7 [15480035.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1663-6 [16033078.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7454-9 [16234512.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):995-1001 [16343175.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1094-100 [16803491.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1750-8 [1551060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(3):491-9 [1612949.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):648-55 [1623479.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):175-80 [2227592.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):9-16 [8175451.001]
  • (PMID = 20379443.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2849943
  • [Keywords] NOTNLM ; Cervical neoplasms / Chemoradiation therapy / MRI / Tumor volume
  •  go-up   go-down


2. Lim MC, Kim JY, Kim TH, Park S, Kong SY, Yoon JH, Kang S, Seo SS, Park SY: Allogeneic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer. Yonsei Med J; 2008 Dec 31;49(6):993-1003
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer.
  • PURPOSE: To analyze the effect of allogeneic blood transfusion on clinical outcome in 119 patients with stage IIB cervical cancer who were treated with radiotherapy +/- chemotherapy.
  • CONCLUSION: Our results suggest that allogeneic blood transfusions given before radiotherapy may be associated with higher incidence of distant metastases and decreased survival in patients with stage IIB cervical cancer.
  • [MeSH-major] Blood Transfusion / adverse effects. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / etiology. Anemia / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Female. Humans. Middle Aged. Prognosis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Biol. 1999 Oct;75(10):1293-7 [10549606.001]
  • [Cites] Oncology. 2005;69 Suppl 2:17-21 [16244506.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):24-31 [11328275.001]
  • [Cites] Int J Radiat Biol. 2001 Dec;77(12):1185-93 [11747543.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Apr;42(1):65-78 [11923069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1345-55 [12459356.001]
  • [Cites] Strahlenther Onkol. 2002 Dec;178(12):727-31 [12491062.001]
  • [Cites] J Trauma. 2003 May;54(5):908-14 [12777903.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1514-20 [14508840.001]
  • [Cites] Mayo Clin Proc. 2003 Oct;78(10):1274-80 [14531486.001]
  • [Cites] Int J Gynecol Cancer. 2003 Sep-Oct;13(5):633-9 [14675347.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70 [14967443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):67-71 [15093900.001]
  • [Cites] Circulation. 2004 Jun 8;109(22):2755-60 [15148271.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):903-10 [15361202.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):145-51 [15385124.001]
  • [Cites] Radiology. 1975 Nov;117(2):459-65 [1178882.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4677-81 [2547512.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):996-1002 [8253537.001]
  • [Cites] Surgery. 1994 Mar;115(3):303-9 [8128355.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):340-4 [7943591.001]
  • [Cites] Arch Surg. 1996 Apr;131(4):438-41 [8615733.001]
  • [Cites] Anesthesiology. 1996 Nov;85(5):1219-20 [8916854.001]
  • [Cites] Vox Sang. 1998;74 Suppl 2:315-9 [9704462.001]
  • [Cites] Strahlenther Onkol. 2004 Nov;180(11):671-81 [15549184.001]
  • [Cites] Am J Obstet Gynecol. 2004 Dec;191(6):1907-13 [15592271.001]
  • [Cites] Cancer Radiother. 2005 Mar;9(2):87-95 [15820436.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):25-36 [16111569.001]
  • [Cites] Hematology. 2005;10 Suppl 1:208-14 [16188675.001]
  • [Cites] Radiother Oncol. 2000 Oct;57(1):13-9 [11033184.001]
  • (PMID = 19108024.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628023
  •  go-up   go-down


3. Qi Y, Huang JS, Wang DD, Zhang F, Zhang SL: [Expressions of HLA class I antigen and CD8 and their clinical significance in cervical cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec;28(12):2165-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of HLA class I antigen and CD8 and their clinical significance in cervical cancer].
  • OBJECTIVE: To examine the expressions of HLA class I antigen and CD8 in various cervical diseases and investigate their association with cervical cancer.
  • METHODS: The expressions of HLA class I antigen and CD8 in cervical tissues sampled from patients with cervical cancer, cervical intraepithelial neoplasia (CIN), and chronic cervicitis were detected using SP immunohistochemistry.
  • RESULTS: The positive expression rates of HLA class I antigen in cervical cancer, CIN, and chronic cervicitis were 22.6%, 100.0%, and 100.0%, and the positive expression rates of CD8 were 22.6%, 95.5%, and 100.0%, respectively.
  • The positive rates of HLA class I antigen and CD8 were significantly lower in patients with cervical cancer (P<0.01).
  • Patients with stage I cervical cancer had significantly higher positive rates of HLA class I antigen and CD8 than those with stage II cervical cancer (46.7% vs 0.0%, 46.7% vs 0.0%, both P<0.01).
  • CONCLUSION: The expressions of HLA class I antigen and CD8 are down-regulated or deleted in CIN and cervical cancer, and they may play important roles in the development and progression of CIN and cervical cancer.
  • [MeSH-major] Antigens, CD8 / immunology. Cervical Intraepithelial Neoplasia / immunology. Histocompatibility Antigens Class I / immunology. Uterine Cervical Neoplasms / immunology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19114347.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD8; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


Advertisement
4. Kim YS, Shin SS, Choi EK, Kim JH, Ahn SD, Lee SW, Park HJ, Kim YT, Mok JE, Nam JH: A preliminary results of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer. Cancer Res Treat; 2005 Feb;37(1):37-43
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preliminary results of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer.
  • PURPOSE: To determine the superior chemotherapeutic regimen between monthly 5-FU plus cisplatin (FP) and weekly cisplatin alone in concurrent chemoradiotherapy for locally advanced cervical cancer, the compliance of treatment, response, survival and toxicities were analyzed between the two arms.
  • MATERIALS AND METHODS: Between March 1998 and December 2001, 61 patients with locally advanced cervical cancer (stage IIB through IVA) and negative para-aortic lymph nodes were randomly assigned to either 'monthly FP' (arm I, n=34) or 'weekly cisplatin' (arm II, n=27) with concurrent radiotherapy.
  • The patients of arm I received FP (5-FU 1,000 mg/m(2)/day + cisplatin 20 mg/m(2)/day, for 5 days, for 3 cycles at 4 week intervals) and those of arm II received cisplatin (30 mg/m(2)/day, for 6 cycles at 1 week intervals) with concurrent radiotherapy.
  • The complete response rates at 3 months were 96 and 88% in arms I and II, respectively.
  • The 4-year overall survival and disease free survival rates were 64 and 54% in the arm I and 77 and 66% in the arm II, respectively.
  • The incidence of hematologic toxicity more than grade 2 was 29% in the arm I and 15% in the arm II.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 May 1;55(9 Suppl):2123-30 [3884135.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403-26 [3549645.001]
  • [Cites] Radiology. 1975 Jun;115(3):681-5 [1129485.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):30-7 [10385548.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Am J Clin Oncol. 1996 Feb;19(1):1-6 [8554027.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1301-7 [7635769.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):444-51 [7844607.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):307-15 [7522200.001]
  • [Cites] Gynecol Oncol. 1993 Jun;49(3):311-7 [8314532.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):391-7 [8436516.001]
  • [Cites] Radiother Oncol. 1992 Dec;25(4):273-9 [1480773.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):970-7 [1709686.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2451-6 [2249184.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):541-9 [3104249.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):230-5 [2915239.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):389-95 [2921143.001]
  • [Cites] Am J Obstet Gynecol. 1983 Dec 1;147(7):803-8 [6359885.001]
  • (PMID = 19956508.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2785420
  • [Keywords] NOTNLM ; Cervical neoplasm / Concurrent chemoradiotherapy / Randomized trials
  •  go-up   go-down


5. Corrado G, Santaguida S, Zannoni G, Scambia G, Ferrandina G: Femur metastasis in carcinoma of the uterine cervix: a rare entity. Arch Gynecol Obstet; 2010 May;281(5):963-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Femur metastasis in carcinoma of the uterine cervix: a rare entity.
  • PURPOSE: We report the first case of isolated femur metastasis in a locally advanced cervical cancer (LACC) patients.
  • CASE: A 40-year-old woman presenting with carcinoma of the uterine cervix, FIGO stage IIb was administered concomitant chemo-radiation and achieved clinical partial response.
  • [MeSH-major] Carcinoma / secondary. Femoral Neoplasms / secondary. Femur / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):420-4 [19553814.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1085-91 [19880262.001]
  • [Cites] Oncologist. 2002;7(4):342-7 [12185296.001]
  • [Cites] J Cancer Res Ther. 2006 Apr-Jun;2(2):79-81 [17998682.001]
  • [Cites] Gynecol Oncol. 1989 Jan;32(1):72-5 [2909450.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S103-16; quiz S264-5 [10517448.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S127-32 [17727936.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3113-9 [15284262.001]
  • (PMID = 19953258.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2848922
  •  go-up   go-down


6. Pasricha R, Tiwari A, Aggarwal T, Lal P: Carcinoma of uterine cervix with isolated metastasis to fibula and its unusual behavior: report of a case and review of literature. J Cancer Res Ther; 2006 Apr-Jun;2(2):79-81
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of uterine cervix with isolated metastasis to fibula and its unusual behavior: report of a case and review of literature.
  • Bone metastasis from carcinoma cervix is uncommon, especially in the distal appendicular skeleton.
  • A 36 year old lady presented with carcinoma of uterine cervix, FIGO, stage IIb.
  • This is one of the few documented cases of metastasis to fibula, arising from carcinoma of uterine cervix and probably the first with isolated metastasis of this site.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Fibula / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998682.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


7. Ivanov S: [Wertheim-Meigs radical hysterectomy for cervical cancer stage IIB]. Akush Ginekol (Sofiia); 2007;46(2):22-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Wertheim-Meigs radical hysterectomy for cervical cancer stage IIB].
  • AIM: Our aim was to examine the patients with stage IIB cervical cancer and the use of radical surgical approach-radical hysterectomy Wertheim-Meigs type.
  • MATERIAL AND METHODS: 450 patients were examined for the period of 1995 till 2006, all of them stage IIB cervical cancer.
  • CONCLUSIONS: The use of radical hysterectomy with pelvic lymph node dissection leads to better results in patients with IIB stage cervical cancer.
  • [MeSH-major] Hysterectomy / methods. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17469447.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


8. Suprasert P, Srisomboon J, Kasamatsu T: Radical hysterectomy for stage IIB cervical cancer: a review. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):995-1001
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical hysterectomy for stage IIB cervical cancer: a review.
  • Patients with stage IIB cervical cancer in some countries in Europe and Asia especially in Japan are usually treated with radical hysterectomy and pelvic lymphadenectomy.
  • We present the literature review of radical hysterectomy in stage IIB cervical cancer by searching data since 1980 from Medline, and we found that the parametrial involvement of patients in this stage was only 21-55%, the incidence of pelvic node metastases was about 35-45%, and 5-year survival rate was between 55% and 77%.
  • Lymph node metastases and the number of positive nodes were significant prognostic factors of patients in this stage.
  • [MeSH-major] Hysterectomy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343175.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


9. Lataifeh I, Amarin Z, Jaradat I: Stage IIB carcinoma of the cervix that is associated with pelvic kidney: A therapeutic dilemma. Am J Obstet Gynecol; 2007 Dec;197(6):e8-10
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IIB carcinoma of the cervix that is associated with pelvic kidney: A therapeutic dilemma.
  • Locally advanced cervical cancer with congenital pelvic kidney is reported uncommonly.
  • A 50-year-old patient with stage IIB cervical cancer and pelvic kidney was treated with irradiation and concurrent chemotherapy.
  • [MeSH-major] Kidney / abnormalities. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060936.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Manfredi R, Gui B, Giovanzana A, Marini S, Di Stefano M, Zannoni G, Scambia G, Bonomo L: Localized cervical cancer (stage &lt;IIB): accuracy of MR imaging in planning less extensive surgery. Radiol Med; 2009 Sep;114(6):960-75
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized cervical cancer (stage <IIB): accuracy of MR imaging in planning less extensive surgery.
  • PURPOSE: This study was undertaken to determine the accuracy of magnetic resonance (MR) imaging in the preoperative staging of patients with clinically localised cervical cancer eligible for less extensive surgery.
  • MATERIALS AND METHODS: Fifty-three patients with biopsy-proven carcinoma of the uterine cervix and eligible for conservative surgery prospectively underwent MR imaging.
  • Images were assessed for tumour site and size, infiltration of the cervical stroma, infiltration of vaginal fornices and relationship between the tumour and the internal os of the endocervical canal and the presence and dimensions of pelvic and lumboaortic lymph nodes (cutoff values 1 cm and 0.5 cm minimum axial diameter).
  • RESULTS: The endocervix was the site of origin of 25% (13/53) of the cervical tumours and the exocervix the site of origin of 75% (40/53).
  • In the assessment of cervical stroma infiltration, there was agreement between MR imaging and histopathology in 75% of cases.
  • CONCLUSIONS: MR imaging had a high level of accuracy in the preoperative assessment of the extent of cervical tumour in patients eligible for conservative surgery.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Magnetic Resonance Imaging / methods. Uterine Cervical Neoplasms / pathology


11. Devkota B, Patel H: Meningeal carcinomatosis from cervical cancer: a case report and review of the literature. Hosp Pract (1995); 2010;38(3):117-21
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal carcinomatosis from cervical cancer: a case report and review of the literature.
  • Meningeal carcinomatosis (MC) from cervical cancer is rare.
  • We report an interesting case of MC from the uterine cervix and review general diagnostic and treatment considerations.
  • The patient received chemotherapy and radiotherapy for stage IIB cervical cancer with resolution of symptoms for 3 years.
  • [MeSH-major] Meningeal Carcinomatosis / secondary. Neoplasms, Squamous Cell / secondary. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890060.001).
  • [ISSN] 2154-8331
  • [Journal-full-title] Hospital practice (1995)
  • [ISO-abbreviation] Hosp Pract (1995)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; cervical cancer / intrathecal / leptomeninges / meningeal carcinomatosis
  •  go-up   go-down


12. Mandic A, Novakovic P, Mihajlovic O, Stojiljkovic B, Rajovic J, Davidovic M: Clinical staging and histopathological findings after radical hysterectomy in FIGO stage IIB cervical cancer. J BUON; 2008 Jan-Mar;13(1):51-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical staging and histopathological findings after radical hysterectomy in FIGO stage IIB cervical cancer.
  • PURPOSE: Advanced cervical cancer still represents a major health care challenge in the developing world.
  • According to standard protocols the treatment of choice for stage IIB cervical cancer is cisplatin-based chemoradiotherapy.
  • However, in some European countries, and especially in Japan, patients with stage IIB cervical cancer are generally treated with radical hysterectomy as initial treatment.
  • The aim of this study was to compare clinical stage with pathological findings, and also to correlate any relationship between parametrial infiltration and nodal status.
  • PATIENTS AND METHODS: From 1997 to 2006, 26 patients with FIGO stage IIB cervical cancer were radically operated (Piver class III operation).
  • The histopathological types of cervical tumors were: squamous cell carcinoma 80%, adenosquamous carcinoma 15% and adenocarcinoma 5%.
  • [MeSH-major] Hysterectomy. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404786.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Wu YY, Liang MR, Li LY, Zeng SY: [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007]. Zhonghua Fu Chan Ke Za Zhi; 2008 Jun;43(6):433-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007].
  • OBJECTIVE: To analyze the changes in epidemiology and treatment of hospitalized patients with cervical cancer during 1990-2007.
  • METHODS: Overall, 4648 patients with cervical cancer were diagnosed in our hospital from Jan 1990 to Nov 2007, but only 4223 patients with initial treatment in our hospital were studied retrospectively.
  • Pearson Chi-square test was used to compare the age, stage, histopathologic type and treatment methods between different times. RESULTS:.
  • (1) The mean age of cervical cancer patients gradually decreased over the past 18 years, from 54.4 years during 1990-1999 to 47.2 years during 2000-2007; the proportion of young patients aged < or = 35 years increased from 4.77% (89/1865) during 1990-1999 to 11.75% (277/2358) during 2000-2007. (2) The proportion of patients with cervical cancer (stage I a-II a) increased from 14.
  • 32% (267/1865) during 1990-1999 to 40.75% (961/2358) during 2000-2007, whereas the proportion of patients with cervical cancer (stage II b-IV) decreased from 85.68% (1598/1865) during 1990-1999 to 59.25% (1397/2358) during 2000-2007. (3) There was no significant change in histopathologic type of cervical cancer, and squamous cell carcinoma of cervix remained the main type of cervical cancer. (4) The treatment pattern of cervical cancer changed significantly: radiotherapy was the main method (75.28%) for cervical cancer during 1990-1999, but during 2000-2007, it was replaced by concurrent chemoradiotherapy (35.79%).
  • CONCLUSIONS: The proportion of young women with cervical cancer was increased during 1990-2007, and at the same period early stage cervical cancer increased, but late stage cervical cancer decreased.
  • It is obvious that chemotherapy has become the important therapy in cervical cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell. Uterine Cervical Neoplasms
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Protocols. Cervix Uteri / pathology. Combined Modality Therapy. Female. Humans. Incidence. Inpatients. Middle Aged. Neoplasm Staging. Radiotherapy. Retrospective Studies


14. Kennedy CM, Peterson LB, Galask RP: Erosive vulvar lichen planus: a cohort at risk for cancer? J Reprod Med; 2008 Oct;53(10):781-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erosive vulvar lichen planus: a cohort at risk for cancer?
  • OBJECTIVE: To determine the occurrence of cancer, including vulvovaginal squamous cell carcinoma (SCC), among women after diagnosis of erosive vulvar lichen planus (LP).
  • RESULTS: A diagnosis of cancer was made in 5 women after diagnosis of erosive vulvar LP.
  • Of these, 1 had stage II vulvar SCC after treatment for stage IIB cervical cancer, and 2 with oral LP had subsequent diagnoses of oral or esophageal SCC.
  • The remaining 2 cancer diagnoses included cervical adenocarcinoma in situ and rectal adenocarcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Lichen Planus / epidemiology. Vulvar Diseases / epidemiology. Vulvar Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004404.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 1K23 HD045769
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


15. Moodley M: Round worm infestation as a cause of small bowel anastomotic breakdown following urinary diversion for cervical cancer. Gynecol Oncol; 2007 Dec;107(3):590-1
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Round worm infestation as a cause of small bowel anastomotic breakdown following urinary diversion for cervical cancer.
  • BACKGROUND: Vesicovaginal fistulae are well-recognized complications of radiotherapy for the treatment of cervical cancer.
  • CASE: A patient with stage IIB cervical cancer presented with a vesicovaginal fistula 6 years post-radiotherapy.
  • [MeSH-major] Anastomosis, Surgical. Ascariasis / complications. Ileum / parasitology. Postoperative Complications / parasitology. Urinary Diversion. Uterine Cervical Neoplasms / surgery. Vesicovaginal Fistula / surgery


16. Nagai T, Okubo T, Sakaguchi R, Seki H, Takeda S: Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy. Int J Clin Oncol; 2008 Dec;13(6):541-4
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy.
  • Described as a poorly differentiated adenosquamous cancer, glassy cell carcinoma of the uterine cervix is a rare disease considered to have an extremely poor prognosis.
  • Saitama Medical Center has been offering neoadjuvant intraarterial chemotherapy (NAC) to cervical cancer patients as a means of avoiding postoperative radiation therapy, achieving downstaging, and improving prognosis.
  • We report a patient with glassy cell carcinoma of the uterine cervix who responded to NAC, and we discuss this case with reference to reports in the literature.
  • A 28-year-old gravida 1, para 0 patient was referred to the Department of Obstetrics and Gynecology at Saitama Medical Center for concurrent cervical cancer at 23.5 gestational weeks.
  • The patient was admitted to our center following the diagnosis of stage IIb cervical cancer (glassy cell carcinoma), to await fetal development, and an elective cesarean section was performed at slightly more than 29 gestational weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19093183.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


17. Tian ZZ, Li S, Liu ML, Zhu XH, Zhao R, Yue YJ, Chen XH: [Clinical value of the comprehensive treatment in intermediate and advanced cervical cancer with uterine arterial interventional chemoembolization and radiotherapy]. Zhonghua Fu Chan Ke Za Zhi; 2010 Jul;45(7):506-10
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of the comprehensive treatment in intermediate and advanced cervical cancer with uterine arterial interventional chemoembolization and radiotherapy].
  • OBJECTIVE: To investigate the long-term curative effect of the radiotherapy combined uterine arterial interventional chemoembolization for cervical cancer.
  • METHODS: Records of 632 patients with cervical cancer stage II - IVa proved by pathology in Lanzhou Command General Hospital from January 1st, 1999 to August 31st, 2009 were retrospective analysed.
  • One hundred and twenty-six cases of them were treated with radical radiotherapy combined uterine arterial interventional chemoembolization (arterial chemoembolization + radiotherapy group), 506 cases of them were treated with radical radiotherapy only (radiotherapy group); the evaluation of the late radiation injury was done, according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) advanced radiation injury criteria.
  • During the follow-up period, the rate of recurrence and metastasis in arterial chemoembolization + radiotherapy group were 77.0% (97/126), while 73.3% (371/506) in radiotherapy group (χ(2) = 0.705, P = 0.401). (2) Radiotherapy complications and relative risk factors: the total incidence of tardive bladder injury higher than RTOG/EORTC stage II was 5.5% (35/632), while it was 11.1% (14/126) in arterial chemoembolization + radiotherapy group, 4.2% (21/506) in the radiotherapy group (χ(2) = 9.344, P = 0.002).
  • The results of logistic regression showed that the uterine arterial interventional chemoembolization was relative risk factors of the tardive bladder injury (χ(2) = 6.440, OR = 2.869, P = 0.011).
  • CONCLUSIONS: Compared with the simple radiotherapy, there are a similar short-term survival rate and significant poor 5-year, 8-year survival rate in the patients treated with the uterine arterial interventional chemoembolization combined with radiotherapy, which also may be strong dangerous factor for the occurrence of tardive bladder injury.
  • The results shown that the uterine arterial interventional chemoembolization do not recommend to be routine adjuvant therapy for the radical radiotherapy of cervical cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / therapy. Chemoembolization, Therapeutic. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Radiotherapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Middle Aged. Neoplasm Staging. Prognosis. Radiography, Interventional. Retrospective Studies. Survival Rate. Treatment Outcome. Uterine Artery. Young Adult


18. Cheng SL, Wang HC, Yang PC: Acute respiratory distress syndrome and lung fibrosis after ingestion of a high dose of ortho-phenylphenol. J Formos Med Assoc; 2005 Aug;104(8):585-7
Hazardous Substances Data Bank. o-Phenylphenol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a suicidal 39-year-old woman with stage II cervical cancer who drank a potentially lethal dose of OPP in the form of a commercial antiseptic, which led to the complication of liver and renal function impairment, severe lung damage with acute respiratory distress syndrome and subsequent severe lung fibrosis.

  • Genetic Alliance. consumer health - Acute Respiratory Distress Syndrome.
  • MedlinePlus Health Information. consumer health - Pulmonary Fibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193180.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biphenyl Compounds; D343Z75HT8 / 2-phenylphenol
  •  go-up   go-down


19. Chen YL, He GQ, Wang ED: [Effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):231-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion].
  • OBJECTIVE: To evaluate the effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion.
  • METHODS: One hundred and eighty-six patients with bulky cervical cancer were randomly divided into two groups: chemotherapy + radiotherapy group (C + R group, n = 105) and radiotherapy group (R group, n = 81).
  • The effective rate for clinical Ib stage cancer in C + R group was 100.0%, significantly higher than 78.3% in R group (P < 0.01), but for clinical IIa, IIb stage cancers, the effective rate between two groups had no obvious difference (P > 0.05).
  • Postoperative pathologic examinations showed the percentage of cervical tumor residue, parauterine invasion, pelvic lymph node metastasis in C + R group was lower than those of R group (P < 0.01).
  • CONCLUSIONS: Internal iliac arterial infusion chemotherapy can effectively reduce tumor volume, decrease lymph node and subclinical metastasis rates and postoperative recurrence rate; it can also improve radical resectability of patients with stage IIb cervical cancer.
  • [MeSH-major] Preoperative Period. Uterine Cervical Neoplasms / drug therapy


20. Kritcharoen S, Suwan K, Jirojwong S: Perceptions of gender roles, gender power relationships, and sexuality in Thai women following diagnosis and treatment for cervical cancer. Oncol Nurs Forum; 2005 May;32(3):682-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perceptions of gender roles, gender power relationships, and sexuality in Thai women following diagnosis and treatment for cervical cancer.
  • PURPOSE/OBJECTIVES: To describe patients' and their partners' perceptions of gender roles, gender power relationships, and sexuality before diagnosis of and after treatment for cervical cancer.
  • SAMPLE: 97 women with cervical cancer who received cancer treatment, including radiotherapy, and their partners.
  • FINDINGS: Fifty-two percent of the women (n = 50) were diagnosed with stage II cervical cancer.
  • An increased percentage of partners undertook the women's gender-role-specific activities after the women received cancer treatment compared with the percentage who did so before diagnosis.
  • A high percentage of the couples reported changes in various aspects of their sexuality after cancer treatment compared with before diagnosis.
  • CONCLUSIONS: Gender roles, gender power relationships, and sexuality changed for women with cervical cancer and their partners after the women completed cancer treatment.
  • IMPLICATIONS FOR NURSING: Open discussions among women with cervical cancer, their partners, and oncology nurses are necessary to identify culturally sensitive and appropriate solutions.
  • [MeSH-major] Gender Identity. Power (Psychology). Sexuality. Uterine Cervical Neoplasms / psychology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Sexual Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897942.001).
  • [ISSN] 1538-0688
  • [Journal-full-title] Oncology nursing forum
  • [ISO-abbreviation] Oncol Nurs Forum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Chen YW, Huang MY, Hou PN, Chang CC, Lee CS, Lian SL: FDG PET/CT delayed diuretic imaging technique for differentiating invasive pelvic cancer. Clin Nucl Med; 2009 Apr;34(4):233-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET/CT delayed diuretic imaging technique for differentiating invasive pelvic cancer.
  • A 72-year-old woman was diagnosed as having a International Federation of Gynecology and Obstetrics (FIGO II) stage cervical cancer with diffuse uterus corpus invasion without evidence of rectal or urinary bladder invasion as determined by endoscopic examinations.
  • Recently, 2 sharp elevations of serum tumor marker squamous cell carcinoma (SCC) were noted while she was receiving radiation therapy.
  • Therefore, a PET/CT scan was performed using fluorodeoxyglucose (FDG) to restage the cervical cancer.
  • FDG-avid cervical tumor was shown to extend into the anterior uterine wall by use of a diuretic imaging technique, which lowered tracer activity in the bladder and improved visualization of lower pelvic structures, which otherwise might have been obscured by urine-FDG activity.
  • [MeSH-major] Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Radiopharmaceuticals. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300055.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Papp Z, Csapó Z, Mayer A, Hupuczi P: [Wertheim-operation: 5-year survival of 501 consecutive patients with cervical cancer]. Orv Hetil; 2006 Mar 26;147(12):537-45
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Wertheim-operation: 5-year survival of 501 consecutive patients with cervical cancer].
  • OBJECTIVE: The purpose of this study was to assess the 5-year survival and morbidity when radical hysterectomy and pelvic lymphadenectomy with pre- and postoperative radiation have been performed for IA2-IIB stage cervical cancer.
  • STUDY DESIGN: During a 10 and a half year period between July, 1990 and December, 2000, 501 consecutive radical hysterectomies with bilateral pelvic lymphadenectomies were performed by the same gynecological surgeon for stage IA2, IB, IIA and IIB carcinoma of the cervix at the I.
  • The absolute 5-year survival rates for the patients in stage IA2, IB1, IB2, IIA and IIB were 94,4%, 90,7%, 84,1%, 71,1% and 55,4%, respectively.
  • The respective 5-year survival rates for patients without or with lymph node metastasis, were 94,5% and 33,3% in stage IB2, 81,7% and 48,7% in stage IIA and 70,2% and 36,5% in stage IIB, respectively.
  • CONCLUSION: Nerve-sparing radical abdominal hysterectomy with pelvic lymph node dissection and pre- and postoperative irradiation remains the treatment of choice for most patients with early-stage and even in IIB-stage cervical cancer.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / surgery. Hysterectomy / adverse effects. Hysterectomy / methods. Lymph Node Excision. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / surgery


23. Singh H, Jain M, Mittal B: MMP-7 (-181A&gt;G) promoter polymorphisms and risk for cervical cancer. Gynecol Oncol; 2008 Jul;110(1):71-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer.
  • Therefore, we aimed to investigate the association of MMP-7 -181A>G gene polymorphism with risk of cervical cancer.
  • METHODS: In the present case control study, we enrolled a total of 150 cervical cancer patients confirmed by histopathology and 162 unrelated healthy individuals.
  • RESULTS: Frequency of MMP-7 -181GG genotype and -181G allele differed significantly between patients with cervical cancer (29.3%) and healthy individuals (19.4%) (P=0.041; OR(GG)=1.94 and P=0.048; OR(G)=1.94).
  • Individuals with MMP-7 -181GG genotype were at higher risk of stage II of cervical cancer with borderline significance (P=0.05, OR=2.78; 95%CI: 0.89-8.69).
  • However, interaction of MMP-7 -181AG and GG genotypes with tobacco usage did not modulate the cervical cancer risk significantly (OR 2.21, 95%CI=0.59-8.1 and OR 3.17, 95%CI=0.64-15.7).
  • CONCLUSION: Individuals with MMP-7 -181GG genotype were at significantly higher risk of cervical cancer.
  • [MeSH-major] Matrix Metalloproteinase 7 / genetics. Polymorphism, Genetic. Promoter Regions, Genetic. Uterine Cervical Neoplasms / genetics

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18448157.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


24. Singh H, Jain M, Mittal B: Role of TGF-beta1 (-509C&gt;T) promoter polymorphism in susceptibility to cervical cancer. Oncol Res; 2009;18(1):41-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of TGF-beta1 (-509C>T) promoter polymorphism in susceptibility to cervical cancer.
  • The aim of study was to evaluate the association of TGF-beta1 -509 C>T gene polymorphism with risk of cervical cancer.
  • The study was carried out in 150 histopathology confirmed patients with cervical cancer and 162 cervical-cytology negative females.
  • Frequencies of individuals with -509TT genotype and T allele of TGF-beta1 gene polymorphisms did not differ significantly in patients with cervical cancer and controls (p = 0.328, OR = 1.37 and p = 0.605, OR = 1.09).
  • Cervical cancer patients with -509TT had marginal low risk for stage I (p = 0.04, OR = 0.95, 95% CI = 0.91-0.99) but -509TT genotype of TGF-beta1 was associated with increased risk of stage II of cancer (p = 0.07, OR = 3.13, 95% CI = 0.87-11.14).
  • In gene-environment interaction, carriers of TGF-beta1 -509TT genotype with tobacco usage were at higher risk of cervical cancer (OR = 3.67, 95% CI = 0.38-35.1).
  • In conclusion, our data suggest that TGF-beta1 -509T allele confers marginal protection for early stage 1B but risk for stage II of cervical cancer.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Polymorphism, Single Nucleotide / genetics. Promoter Regions, Genetic / genetics. Transforming Growth Factor beta1 / genetics. Uterine Cervical Neoplasms / genetics

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911703.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; 0W860991D6 / Deoxycytidine; VC2W18DGKR / Thymidine
  •  go-up   go-down


25. Yamashita H, Okuma K, Kawana K, Nakagawa S, Oda K, Yano T, Kobayashi S, Wakui R, Ohtomo K, Nakagawa K: Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study. Am J Clin Oncol; 2010 Dec;33(6):583-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study.
  • OBJECTIVE: To compare treatment outcome of conventional surgery followed by adjuvant postoperative radiotherapy (PORT) versus concurrent chemoradiation therapy (cCRT) for stage IIB cervical carcinoma.
  • METHODS: A retrospective analysis was conducted of 59 patients with stage IIB uterine cervical cancer treated with radical surgery plus PORT (N = 34) or cCRT-alone (N = 25) from April 1996 to June 2008.
  • CONCLUSION: This retrospective study suggests that survival results with cCRT and with conventional surgery plus PORT for patients with stage IIB cervical carcinoma are comparable.
  • [MeSH-major] Hysterectomy / methods. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065848.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Shi HR, Wu QH, Suo ZH, Nesland JM: [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer]. Ai Zheng; 2005 Jan;24(1):7-11
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
  • This study was designed to explore relationship of methylation of 5'-CpG islands with inactivation of FHIT gene in cervical cancer.
  • METHODS: Methylation of 5'-CpG islands in 10 normal cervical squamous epithelial tissues, and 40 cervical cancer tissues was detected with methylation specific polymerase chain reaction (MSP), protein expression of FHIT was detected with immunohistochemistry, and their correlations with clinicopathologic features of cervical cancer were statistically analyzed. RESULTS:.
  • (1) The 5'-CpG islands methylation rate of FHIT gene in cervical cancer tissues was 40.0% (16/40), while no methylation of FHIT gene was found in normal cervical tissues. (2) The methylation rates of FHIT gene in cervical cancer of stage I was 14.3% (2/14), significantly lower than that in cervical cancer of stage II (56.5%, 13/23) (P<0.05). (3) Expression of FHIT protein in cervical cancer was 33.0% (12/40), significantly lower than that in normal cervical tissue (100%, 10/10) (P<0.05).
  • CONCLUSION: The 5'-CpG islands methylation may play an important role in inactivation of FHIT gene, and may be related with tumorigenesis of cervical cancer.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. CpG Islands / genetics. DNA Methylation. Gene Silencing. Neoplasm Proteins / biosynthesis. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Genes, Tumor Suppressor. Humans. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642192.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


27. Chen CH, Chao KC, Wang PH: Advanced cervical squamous cell carcinoma with skin metastasis. Taiwan J Obstet Gynecol; 2007 Sep;46(3):264-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced cervical squamous cell carcinoma with skin metastasis.
  • OBJECTIVE: Although cervical cancer is a very common gynecologic malignancy, skin metastasis presenting as an initial sign of recurrent or persistent disease is extremely rare.
  • CASE REPORT: A 72-year-old woman was diagnosed with squamous cell carcinoma of the cervix (FIGO stage, IIB), which was treated with concurrent chemoradiation.
  • Excision biopsy was performed and showed metastatic carcinoma, favoring a squamous cell type.
  • CONCLUSION: This report supports the concept that skin metastasis is a late manifestation and an ominous sign for cervical cancer patients, and also indicates the uncontrolled or widespread metastasis of the disease.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962107.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Ubieto MA, Paredes P, Martínez S, Ortín J, Fuster D, Torné A, Setoain FJ, Pahisa J, Pons F, Lomeña F: [Ovarian and para-aortic recurrence from cervix cancer detected by PET/CT]. Rev Esp Med Nucl; 2006 Jan-Feb;25(1):31-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian and para-aortic recurrence from cervix cancer detected by PET/CT].
  • [Transliterated title] Recurrencia ovárica y paraaórtica de un carcinoma de cuello uterino detectada mediante PET/TC.
  • We present the case of a 34-year-old woman diagnosed of an adenosquamous carcinoma of the uterine cervix, stage IIB of the FIGO classification (International Federation of Gynecology and Obstetrics), treated with quimiotherapy, radiotheraphy and brachytheraphy with posterior hysterectomy.
  • PET with FDG (F18-fluorodeoxyglucose) is useful in the staging of primary tumour and in the detection of recurrence in uterine cervical carcinoma, with better sensitivity and specificity than CT and MRI.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Lymphatic Metastasis / diagnosis. Ovarian Neoplasms / secondary. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Brachytherapy. Carcinoma, Squamous Cell / diagnosis. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Hysterectomy. Radiotherapy, Adjuvant. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540009.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Gupta T, Nair N, Fuke P, Bedre G, Basu S, Shrivastava SK: Splenic metastases from cervical carcinoma: a case report. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):911-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic metastases from cervical carcinoma: a case report.
  • Splenic metastasis from squamous cell carcinoma of the uterine cervix is an unusual event in the natural history of the disease.
  • The authors report one such uncommon occurrence in a 41-year-old female who presented initially with cervical carcinoma (stage IIB) and was treated with radical radiotherapy with concurrent weekly chemotherapy.
  • This report reaffirms the notion that splenic metastases from cervical carcinoma are rare events but can occur as part of widespread dissemination.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Splenic Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681784.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Gupta G, Hafiz A, Gandhi JS: Radiation-induced chondrosarcomas: a case report with review of literature. J Cancer Res Ther; 2010 Jul-Sep;6(3):394-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation therapy has become an important component of various cancer treatments.
  • We report a rare case of RIS of left iliac bone in a 62-year-old lady after combined chemotherapy and external beam radiation therapy for cervical carcinoma (stage IIb).
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Uterine Cervical Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119289.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


31. Haberstich R, Minetti A, Hamid D, Meyer C, Hoffbeck A, Baldauf JJ: [Left colon necrosis after endoscopic para-aortic lymph node exploration in a cervical carcinoma stage IIB]. Ann Chir; 2006 Nov;131(9):553-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Left colon necrosis after endoscopic para-aortic lymph node exploration in a cervical carcinoma stage IIB].
  • [Transliterated title] Nécrose colique gauche après un curage lomboaortique coelioscopique pour cancer du col utérin de stade IIB.
  • Authors report a left colon ischemia six days after laparoscopic para-aortic lymphadenectomy in the staging of advanced cervical carcinoma.
  • [MeSH-major] Colon / pathology. Laparoscopy. Lymph Node Excision / adverse effects. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626620.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


32. Kümmel S, Thomas A, Jeschke S, Hauschild M, Sehouli J, Lichtenegger W, Blohmer JU: Postoperative therapy modalities for cervical carcinoma. Anticancer Res; 2006 Mar-Apr;26(2C):1707-13
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative therapy modalities for cervical carcinoma.
  • Currently, the standard therapy for cervical carcinoma of FIGO stage IIB following adequate radical surgery is simultaneous radiochemotherapy with a platinous chemotherapeutic agent.
  • According to the current state of scientific knowledge, all patients of FIGO stages IIA-IB with at least one additional risk factor (adenocarcinoma, pN1, L1, V1, pT1b2) also benefit from adjuvant radiochemotherapy.
  • The data regarding a possible survival advantage following an increase in the hemoglobin content in the blood of cancer patients by erythropoietin administration is still contradictory.
  • Several studies are currently being conducted into the effectiveness of such new therapies on both life expectancy and quality of life (e.g., Cervix-NOGGO-AGO-Uterus 7-study).
  • [MeSH-major] Uterine Cervical Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617565.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hemoglobins
  • [Number-of-references] 63
  •  go-up   go-down


33. Boyd A, Cowie V, Gourley C: The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature. Int J Gynecol Cancer; 2009 Feb;19(2):273-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature.
  • BACKGROUND: Cervical cancer is one of the most frequently encountered malignancies in pregnancy.
  • For early-stage disease arising in late second/third trimester, treatment may be delayed until delivery.
  • CASE: A 26-year-old woman presented at 21 weeks gestation with a stage IIB high-grade clear cell cervical carcinoma.
  • CONCLUSION: Neoadjuvant cisplatin chemotherapy can be used in stage IIB cervical carcinoma during pregnancy to allow fetal development and prevent disease progression before delivery.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy


34. Nasu K, Takai N, Narahara H: Multimodal treatment for glassy cell carcinoma of the uterine cervix. J Obstet Gynaecol Res; 2009 Jun;35(3):584-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment for glassy cell carcinoma of the uterine cervix.
  • Glassy cell carcinoma of the uterine cervix is a rare form of cervical cancer that is characterized by aggressiveness and poor prognosis because of its rapid growth, its frequent distant metastases, and its relative resistance to conventional treatment modalities including surgery, radiotherapy, and chemotherapy.
  • We report here a case of glassy cell carcinoma of the uterine cervix that was successfully treated with radical surgery followed by radiation therapy and combination chemotherapy with paclitaxel and carboplatin.
  • A 30-year-old primigravid Japanese woman was admitted to our hospital to be treated for stage IIb uterine cervical cancer.
  • The pathological diagnosis of the surgical specimen was glassy cell carcinoma of the uterine cervix with metastases to the right obturator lymph nodes and left external iliac lymph nodes.
  • It is suggested that multimodal therapy with radical surgery, radiation, and combined chemotherapy should be used to treat glassy cell carcinoma of the uterine cervix.
  • [MeSH-major] Carcinoma, Adenosquamous / therapy. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527406.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


35. Noh JM, Huh SJ: Two cases of post-radiation osteosarcoma of the sacrum after pelvic irradiation for uterine cervical cancer. Eur J Gynaecol Oncol; 2007;28(6):497-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of post-radiation osteosarcoma of the sacrum after pelvic irradiation for uterine cervical cancer.
  • BACKGROUND: Post-radiation pelvic bone sarcoma can result as a long-term sequela of pelvic irradiation for uterine cervical cancer.
  • CASE: A 59-year-old woman who had received pelvic irradiation for Stage IIB uterine cervical cancer 16 years before was diagnosed as having post-radiation osteosarcoma of the sacrum.
  • Another 66-year-old woman who had received pelvic irradiation for Stage IIIB uterine cervical cancer seven years previously was also diagnosed as having pleomorphic sarcoma of the sacrum.
  • [MeSH-major] Bone Neoplasms / secondary. Neoplasms, Radiation-Induced / etiology. Osteosarcoma / secondary. Sacrum / pathology. Uterine Cervical Neoplasms / radiotherapy


36. Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S: Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation. Gynecol Oncol; 2009 Jul;114(1):69-74
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation.
  • OBJECTIVE: To clarify the clinicopathological features and prognostic factors of patients with FIGO stage IIB cervical cancer who were treated with radical hysterectomy.
  • METHODS: One hundred thirty-nine FIGO stage IIB patients with squamous or adenosquamous cell carcinoma (median age, 51 years) who were treated with primary radical hysterectomy were examined retrospectively.
  • Sixty-six FIGO stage IIB patients who were treated with primary radiotherapy (median age, 70 years) were included for comparison of survival.
  • CONCLUSION: Pathological parametrial involvement and positive nodes were prognostic factors for surgically treated patients with FIGO stage IIB cervical cancer.
  • [MeSH-major] Hysterectomy / methods. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Survivors


37. Gao JM, Zeng YX, Cui NJ, Lu TX, Zhao C, Xia YF, Ma J, Xie FY: [Staging 915 cases of nasopharyngeal carcinoma after simple radical radiotherapy (Part II)--Checkout of AJCC/UICC staging system (1997)]. Ai Zheng; 2006 Mar;25(3):257-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Staging 915 cases of nasopharyngeal carcinoma after simple radical radiotherapy (Part II)--Checkout of AJCC/UICC staging system (1997)].
  • BACKGROUND & OBJECTIVE: On the basis of our previous research, this study was to validate the rationality of AJCC/UICC staging system (1997) of nasopharyngeal carcinoma (NPC), and to provide some suggestions.
  • METHODS: Survival data of 915 NPC patients, received radical radiotherapy alone in Cancer Center of Sun Yat-sen University from Jan.
  • RESULTS: Cox regression analysis showed that the 5-year survival rate of the 915 patients was significantly correlated to their age and tumor stage classified according to AJCC/UICC (1997) staging system; while that of the 803 patients no more than 60 years old was only significantly correlated to tumor stage.
  • Life table analysis validated that the tumor stage classified according to AJCC/UICC staging system can roughly predict the prognosis, but the differences between stage I and IIa, or IVa and IVb were not significant.
  • Kaplan-Meier analysis showed no significant differences of survival rate between stage T1 and T2a, or T3 and T4 when adjusted by N classification, and between stage N2 and N3a, or N3a and N3b when adjusted by T classification.
  • Therefore, we adjusted stage T2a to T1, stage N1 with inferior cervical nodes metastasis to N2, combined stage N3a and N3b to N3, adjusted stage IIa to I, stage IIb to II, and stage IVb to IVa.
  • CONCLUSION: Taking the impact of age on the prognosis and the interaction between T stage and N stage into consideration, the above modifications should be included when renewing the AJCC/UICC staging system (1997).

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536975.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Papp Z, Csapó Z, Hupuczi P, Mayer A: Nerve-sparing radical hysterectomy for stage IA2-IIB cervical cancer: 5-year survival of 501 consecutive cases. Eur J Gynaecol Oncol; 2006;27(6):553-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nerve-sparing radical hysterectomy for stage IA2-IIB cervical cancer: 5-year survival of 501 consecutive cases.
  • OBJECTIVE: The purpose of this study was to assess the 5-year survival and morbidity in cases with radical hysterectomy and pelvic lymphadenectomy with pre- and postoperative irradiation performed to treat Stage IA2-IIB cervical cancer.
  • METHODS: During a 10(1/2)-year period between July 1990 and December 2000, 501 consecutive radical hysterectomies with bilateral pelvic lymphadenectomy were performed by the same gynecological surgeon in Stage IA2, IB, IIA and IIB cervical cancer.
  • The absolute 5-year survival rates for the patients in Stage IA2, IB1, IB2, IIA and IIB were 94.4%, 90.7%, 84.1%, 71.1%, and 55.4%, respectively.
  • The respective 5-year survival rates for patients without or with lymph node metastasis were 94.5% and 33.3% in Stage IB2, 81.7% and 48.7% in Stage IIA and 70.2% and 36.5% in Stage IIB, respectively.
  • CONCLUSIONS: Nerve-sparing radical hysterectomy with pelvic lymph node dissection and pre- and postoperative irradiation remains the treatment of choice for most patients with early-stage and even Stage IIB cervical cancer.
  • [MeSH-major] Hypogastric Plexus / injuries. Hysterectomy / methods. Lymph Node Excision / methods. Pelvic Floor / innervation. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290582.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


39. Saitoh J, Sakurai H, Suzuki Y, Katoh H, Takahashi T, Nakano T: Metastatic angiosarcoma of the lung with alveolar hemorrhage. Jpn J Radiol; 2009 Nov;27(9):381-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 76-year-old woman was diagnosed as stage IIb uterine cervical cancer.
  • The cancer disappeared after radiotherapy.
  • No recurrence of the uterine cervical cancer was detected.
  • [MeSH-major] Hemangiosarcoma / complications. Hemangiosarcoma / secondary. Hemorrhage / etiology. Lung Neoplasms / complications. Lung Neoplasms / secondary. Uterine Cervical Neoplasms / pathology






Advertisement